In this webinar, learn about upcoming changes impacting Medicare Part D enrollees, including the $2,000 cap on out-of-pocket costs and the Medicare Prescription Payment Plan (MPPP). These changes to Medicare prescription drug plans stem from the Inflation Reduction Act (IRA) passed in 2022 and will go into effect in early 2025. The changes impact the affordability of and access to coverage for millions of Americans, including people with HIV.
Presenters from the ACE TA Center, in collaboration with the National Association of State & Territorial AIDS Directors (NASTAD), provide an overview of the $2,000 cap on out-of-pocket costs and the MPPP. Presenters also walk through considerations for Ryan White HIV/AIDS Program (RWHAP) recipients and subrecipients to ensure their clients understand these changes and how to access important new protections. Finally, presenters discuss the impacts of the MPPP on revenue generation for RWHAP recipients.
Learning Objectives
By the end of the webinar, participants will be able to:
- Describe upcoming policy changes to Medicare Part D for the 2025 plan year that will impact RWHAP clients
- Articulate benefits and challenges associated with enrollment into the Medicare Prescription Payment Plan
- Apply best practices to support RWHAP clients navigate major health coverage changes
Supporting Files
Developed by
